Metropolitan Life Insurance Company (MetLife)’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,554
| Closed | -$115K | – | 486 |
|
|
2024
Q1 | $115K | Sell |
4,554
-75
| -2% | -$1.77K | 0.01% | 975 |
|
|
2023
Q4 | $150K | Hold |
4,629
| – | – | 0.01% | 876 |
|
|
2023
Q3 | $126K | Hold |
4,629
| – | – | 0.01% | 898 |
|
|
2023
Q2 | $103K | Sell |
4,629
-280
| -6% | -$6.45K | 0.01% | 1006 |
|
|
2023
Q1 | $106K | Sell |
4,909
-477
| -9% | -$10.5K | 0.01% | 968 |
|
|
2022
Q4 | $109K | Hold |
5,386
| – | – | ﹤0.01% | 1003 |
|
|
2022
Q3 | $138K | Hold |
5,386
| – | – | 0.01% | 838 |
|
|
2022
Q2 | $128K | Hold |
5,386
| – | – | 0.01% | 919 |
|
|
2022
Q1 | $121K | Sell |
5,386
-20,580
| -79% | -$438K | ﹤0.01% | 1079 |
|
|
2021
Q4 | $514K | Hold |
25,966
| – | – | 0.01% | 1399 |
|
|
2021
Q3 | $511K | Sell |
25,966
-2,360
| -8% | -$49.4K | 0.01% | 1449 |
|
|
2021
Q2 | $623K | Buy |
28,326
+1,803
| +7% | +$40.1K | 0.01% | 1371 |
|
|
2021
Q1 | $631K | Sell |
26,523
-996
| -4% | -$26.6K | 0.01% | 1273 |
|
|
2020
Q4 | $720K | Sell |
27,519
-2,902
| -10% | -$61.1K | 0.01% | 1113 |
|
|
2020
Q3 | $529K | Hold |
30,421
| – | – | 0.01% | 1179 |
|
|
2020
Q2 | $512K | Hold |
30,421
| – | – | 0.01% | 1177 |
|
|
2020
Q1 | $362K | Buy |
30,421
+576
| +2% | +$7.13K | 0.01% | 1242 |
|
|
2019
Q4 | $361K | Sell |
29,845
-1,132
| -4% | -$15.8K | 0.01% | 1528 |
|
|
2019
Q3 | $438K | Hold |
30,977
| – | – | 0.01% | 1380 |
|
|
2019
Q2 | $345K | Hold |
30,977
| – | – | 0.01% | 1529 |
|
|
2019
Q1 | $364K | Hold |
30,977
| – | – | 0.01% | 1500 |
|
|
2018
Q4 | $414K | Hold |
30,977
| – | – | 0.01% | 1312 |
|
|
2018
Q3 | $434K | Hold |
30,977
| – | – | 0.01% | 1474 |
|
|
2018
Q2 | $487K | Buy |
30,977
+607
| +2% | +$10.6K | 0.01% | 1329 |
|
|
2018
Q1 | $500K | Buy |
30,370
+514
| +2% | +$9.52K | 0.01% | 1275 |
|
|
2017
Q4 | $539K | Sell |
29,856
-33,141
| -53% | -$600K | 0.01% | 1236 |
|
|
2017
Q3 | $1.22M | Hold |
62,997
| – | – | 0.01% | 1142 |
|
|
2017
Q2 | $743K | Buy |
62,997
+6,694
| +12% | +$72.8K | 0.01% | 1419 |
|
|
2017
Q1 | $617K | Buy |
56,303
+2,992
| +6% | +$26.3K | ﹤0.01% | 1519 |
|
|
2016
Q4 | $387K | Sell |
53,311
-3,933
| -7% | -$30.8K | ﹤0.01% | 1901 |
|
|
2016
Q3 | $372K | Buy |
57,244
+65
| +0.1% | +$378 | ﹤0.01% | 1901 |
|
|
2016
Q2 | $312K | Buy |
57,179
+8,372
| +17% | +$43.5K | ﹤0.01% | 2007 |
|
|
2016
Q1 | $228K | Buy |
48,807
+8,203
| +20% | +$32K | ﹤0.01% | 2093 |
|
|
2015
Q4 | $202K | Hold |
40,604
| – | – | ﹤0.01% | 2265 |
|
|
2015
Q3 | $153K | Buy |
40,604
+1,975
| +5% | +$10K | ﹤0.01% | 2457 |
|
|
2015
Q2 | $232K | Sell |
38,629
-5,373
| -12% | -$32.9K | ﹤0.01% | 2304 |
|
|
2015
Q1 | $246K | Buy |
+44,002
| New | +$159K | ﹤0.01% | 1950 |
|
|
2014
Q2 | – | Sell |
-47,179
| Closed | -$206K | – | 2773 |
|
|
2014
Q1 | $206K | Buy |
+47,179
| New | +$165K | ﹤0.01% | 2440 |
|
Other funds holding CORT
ISL
PA
NHAS
BTW
Metropolitan Life Insurance Company (MetLife)'s CORT Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Corcept Therapeutics (CORT) in Q2 2024, closing a stake of 4,554 shares — an estimated $115K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in CORT in Q1 2014 and held it in 38 quarters. The position peaked at $1.22M in Q3 2017. 285 funds tracked by Wall St. Rank hold CORT as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Corcept Therapeutics position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 4,554 Corcept Therapeutics shares in Q2 2024, an estimated $115K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Corcept Therapeutics in Q1 2014 and held it in 38 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Corcept Therapeutics position peaked at $1.22M in Q3 2017.
- 285 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.